Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ

Singaporean Prime Minister Lee Hsien Loong meets with weifenghe

Luoxin pharmaceutical: fosapitam for injection and meglumine have obtained the drug registration certificate

Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved

A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point

Boeing's revenue in the first quarter was $14 billion, with a market estimate of $15.94 billion.

Tesla unveiled a new giant 360mwh Megapack energy storage project

Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources

The communication service sector opened stronger

Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten

The Italian Ministry of economy said it expected GDP to grow by more than 4% in 2022.

Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%

Yu Minhong responded to New Oriental's business reduction, dismissal and other issues: about 50000 employees remained

Zhejiang Jiaxing further liberalizes settlement conditions

54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare

During the year, the first day earnings of 7 new shares exceeded 100000 yuan, and 14 new shares were broken on the first day of listing